CD437 is a retinoic acid receptor (RAR)γ-selective agonist, γ-selective retinoid; potent inducer of apoptosis. It displays RARγ-dependent and -independent effects on differentiation and apoptosis. CD437 reduces the numbers of H460, SK-MES-1, A549, and H292 cells with 50% inhibitory values of approximately 0.5, 0.4, 3, and 0.85 μM, respectively. Treatment for 72 h with CD437 causes a strong dose-dependent growth inhibition in all melanoma cell lines. At a concentration of 5 μM CD437, only about 5 to 25% of the cells remain viable after 3 d. The concentrations of CD437 required for 50% growth inhibition (IC50) range from 10 μM for MeWo to 0.1 μM for SK-Mel-23 showing the highest sensitivity.
In vivo, tumors in CD437-treated mice stop growing, an effect that becomes already statistically significant (P<0.01) at day 13, 3 d after first administration of CD437, and is maintained for more than 3 wk after discontinuation of treatment. Further histologic analysis demonstrates marked c-fos mRNA levels at the tumor-stroma edge in CD437-treated tumors.
| Cell Experiment | |
|---|---|
| Cell lines | |
| Preparation method | |
| Concentrations | |
| Incubation time | |
| Animal Experiment | |
|---|---|
| Animal models | Male Swiss-nu/nu mice weighing 20 to 25 g |
| Formulation | |
| Dosages | 10 mg/kg/body weight and 30 mg/kg/body weight |
| Administration | injected intratumorally or fed |
| Molecular Weight | 398.49 |
| Formula | C27H26O3 |
| CAS Number | 125316-60-1 |
| Solubility (25°C) | DMSO: 100 mg/mL (Need ultrasonic and warming) |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related RAR/RXR Products |
|---|
| MSU-42011
MSU-42011 is an orally active retinoid X receptor-like (RXR) agonist that potently inhibits the expression of iNOS as well as p-ERK protein levels. In addition, MSU-42011 has immunomodulatory and antitumor activities for cancer research. |
| KCL-286
KCL-286 is an orally active retinoic acid receptor-beta (RAR-beta) agonist for studies related to spinal cord injury. |
| XS-060
XS-060 is a potent anticancer agent and RXRα antagonist. |
| BPA-B9
BPA-B9 is a RXRα ligand and antagonist targeting the pRXRα-PLK1 interaction. |
| ER 50891 quarterhydrate
ER 50891 quarterhydrate is a potent antagonist of retinoic acid receptor α(RARα). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
